{"id":583,"date":"2016-06-02T13:32:22","date_gmt":"2016-06-02T17:32:22","guid":{"rendered":"https:\/\/3sixtypharma.com\/?p=583"},"modified":"2018-01-13T15:01:15","modified_gmt":"2018-01-13T20:01:15","slug":"deadline-july-2-fdas-omb","status":"publish","type":"post","link":"https:\/\/3sixtypharma.com\/2016\/06\/02\/deadline-july-2-fdas-omb\/","title":{"rendered":"Biosimilar nomenclature: Deadline August 2 for comments on FDA’s OMB information request"},"content":{"rendered":"

Meaningful suffix may be in for U.S. biologics, biosimilars<\/a><\/span><\/h1>\n

 <\/p>\n

 <\/p>\n

FDA Pushes Back Comment Period for Biosimilar Labeling<\/a><\/h1>\n

Just released: new deadline August?2 for information collection request it submitted to the White House Office of Management and Budget (OMB)<\/p>\n

 <\/p>\n

 <\/p>\n

Additional Reading<\/span><\/p>\n

FDA approves Inflectra, a biosimilar to Remicade<\/span><\/a><\/span><\/p>\n

A Rocky Start for Biosimilar Inflectra?<\/span><\/a><\/span><\/p>\n

FDA Approves INFLECTRA? (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications<\/span><\/a><\/span><\/p>\n

Sandoz launches ZarxioTM (filgrastim-sndz), the first biosimilar in the United States<\/span><\/a><\/span><\/p>\n

FDA Information on Biosimilars<\/span><\/a><\/span><\/p>\n

Biosimilar switching not suitable for all patients<\/span><\/a><\/span><\/p>\n

 <\/p>\n

 <\/p>\n

\"\"<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Meaningful suffix may be in for U.S. biologics, biosimilars     FDA Pushes Back Comment Period for Biosimilar Labeling Just released: new deadline August?2 for information collection request it submitted to the White House Office of Management and Budget (OMB)     Additional Reading FDA approves Inflectra, a biosimilar to Remicade A Rocky Start for[…]<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","enabled":false}}},"categories":[8],"tags":[54,89,85,86,88,87],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7wLmz-9p","jetpack_likes_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/3sixtypharma.com\/wp-json\/wp\/v2\/posts\/583"}],"collection":[{"href":"https:\/\/3sixtypharma.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/3sixtypharma.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/3sixtypharma.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/3sixtypharma.com\/wp-json\/wp\/v2\/comments?post=583"}],"version-history":[{"count":0,"href":"https:\/\/3sixtypharma.com\/wp-json\/wp\/v2\/posts\/583\/revisions"}],"wp:attachment":[{"href":"https:\/\/3sixtypharma.com\/wp-json\/wp\/v2\/media?parent=583"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/3sixtypharma.com\/wp-json\/wp\/v2\/categories?post=583"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/3sixtypharma.com\/wp-json\/wp\/v2\/tags?post=583"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}